Optimind Pharma

Optimind Pharma Book Value per Share

Book Value per Share of Optimind Pharma (OMND.CN) as of Nov 3, 2026.

Book Value per Share

-0.00CAD

YoY

149.86%

Last updated:

Book Value per Share of Optimind Pharma is 2026 -0.00 CAD. Book Value per Share of Optimind Pharma was 2025 -0.00 CAD. It decreases by 149.86% lower compared to the previous year.

The Optimind Pharma Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
-0.01 CAD
Jan 1, 2019
-0.01 CAD
Jan 1, 2020
-0.00 CAD
Jan 1, 2021
-0.00 CAD
Jan 1, 2023
0.01 CAD
Jan 1, 2024
-0.00 CAD
Jan 1, 2025
-0.00 CAD
Jan 1, 2026
-0.00 CAD
The Optimind Pharma Book Value per Share history
YEARBook Value per ShareYoY
-0.00CAD+149.86%
-0.00CAD-42.00%
-0.00CAD-120.17%
0.01CAD-461.03%
-0.00CAD+119.04%
-0.00CAD-92.55%
-0.01CAD+2.03%
-0.01CAD+26.43%
-0.01CAD-27.81%
-0.01CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Optimind Pharma Stock analysis

What does Optimind Pharma do? Optimind Pharma Corp. generates revenue through medical cannabis and ketamine-assisted treatments for mental health conditions including PTSD, anxiety, and depression. The company offers two treatment types: Monotherapy and assisted therapy, both utilizing ketamine capsules. These programs integrate psychedelic medicine with therapeutic processing, based on scientific research and established therapeutic modalities. The firm partners with psilocybin treatment developers to expand its offerings, targeting patients seeking alternative mental health solutions through psychedelic-enhanced psychotherapy. Optimind Pharma Corp.'s primary customers are individuals suffering from mental illnesses and disabilities, particularly those with PTSD, anxiety, and depression. The company's treatment programs are designed to restore cognitive function within two hours of ketamine capsule administration, appealing to patients seeking rapid therapeutic effects. By combining ketamine with therapeutic integration, the firm addresses a growing market demand for innovative mental health treatments beyond conventional pharmaceuticals. The company's revenue streams include direct patient treatment services and partnerships with psilocybin-associated treatment developers. These partnerships allow Optimind to offer expanded program options without developing new products internally. The focus on scientifically backed psychedelic-enhanced psychotherapy differentiates Optimind in the mental health treatment sector, targeting patients who prefer non-traditional approaches to managing mental health conditions. Optimind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Optimind Pharma stock

On Eulerpool you can find the complete historical development of Book Value per Share Optimind Pharma since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Optimind Pharma

All Key Metrics — Optimind Pharma